199 related articles for article (PubMed ID: 31118465)
1. A revised international prognostic score system for Waldenström's macroglobulinemia.
Kastritis E; Morel P; Duhamel A; Gavriatopoulou M; Kyrtsonis MC; Durot E; Symeonidis A; Laribi K; Hatjiharissi E; Ysebaert L; Vassou A; Giannakoulas N; Merlini G; Repousis P; Varettoni M; Michalis E; Hivert B; Michail M; Katodritou E; Terpos E; Leblond V; Dimopoulos MA
Leukemia; 2019 Nov; 33(11):2654-2661. PubMed ID: 31118465
[TBL] [Abstract][Full Text] [Related]
2. The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia.
Dimopoulos M; Gika D; Zervas K; Kyrtsonis M; Symeonidis A; Anagnostopoulos A; Bourantas K; Matsouka C; Pangalis G
Leuk Lymphoma; 2004 Sep; 45(9):1809-13. PubMed ID: 15223640
[TBL] [Abstract][Full Text] [Related]
3. Treatment and outcome patterns of patients with Waldenström's macroglobulinemia: a large, multicenter retrospective review in China.
Cao XX; Yi SH; Jiang ZX; He JS; Yang W; Du J; Sun CY; Wu Y; Chen WM; Liu XJ; Li BZ; Li CR; Sang W; Liu QH; Chu XX; Li F; Bai O; Mao M; Fu R; Wang W; Liu LH; Wang LQ; Dong YJ; Luo J; Li ZL; Wei YQ; Zhang QK; Liu J; Ding KY; Zou L; Chen BY; Hua LM; Jing HM; He J; Wang L; Li J; Qiu LG
Leuk Lymphoma; 2021 Nov; 62(11):2657-2664. PubMed ID: 34105439
[TBL] [Abstract][Full Text] [Related]
4. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.
Dimopoulos MA; Hamilos G; Zervas K; Symeonidis A; Kouvatseas G; Roussou P; Gika D; Karmiris T; Bourantas K; Zomas A; Mitsouli C; Xilouri I; Vervessou E; Matsis K; Anagnostopoulos N; Economopoulos T;
Ann Oncol; 2003 Aug; 14(8):1299-305. PubMed ID: 12881396
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
[TBL] [Abstract][Full Text] [Related]
6. Excellent long-term survival of 170 patients with Waldenström's macroglobulinemia treated in private oncology practices and a university hospital.
Hensel M; Brust J; Plöger C; Schuster D; Memmer ML; Franz-Werner J; Feustel HP; Karcher A; Fuxius S; Mosthaf FA; Rieger M; Ho AD; Witzens-Harig M
Ann Hematol; 2012 Dec; 91(12):1923-8. PubMed ID: 22895554
[TBL] [Abstract][Full Text] [Related]
7. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
[TBL] [Abstract][Full Text] [Related]
8. Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase.
Kastritis E; Zervas K; Repoussis P; Michali E; Katodrytou E; Zomas A; Simeonidis A; Terpos E; Delimbassi S; Vassou A; Gika D; Dimopoulos MA;
Clin Lymphoma Myeloma; 2009 Mar; 9(1):50-2. PubMed ID: 19362972
[TBL] [Abstract][Full Text] [Related]
9. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH).
Kastritis E; Kyrtsonis MC; Hadjiharissi E; Symeonidis A; Michalis E; Repoussis P; Tsatalas C; Michael M; Sioni A; Kartasis Z; Stefanoudaki E; Voulgarelis M; Delimpasi S; Gavriatopoulou M; Koulieris E; Gika D; Zomas A; Roussou P; Anagnostopoulos N; Economopoulos T; Terpos E; Zervas K; Dimopoulos MA;
Leuk Res; 2010 Oct; 34(10):1340-3. PubMed ID: 20447689
[TBL] [Abstract][Full Text] [Related]
10. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
11. Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.
Guidez S; Labreuche J; Drumez E; Ysebaert L; Bakala J; Delette C; Hivert B; Protin C; Declercq H; Verlay M; Marolleau JP; Duhamel A; Morel P;
Blood Adv; 2018 Nov; 2(22):3102-3111. PubMed ID: 30455359
[TBL] [Abstract][Full Text] [Related]
12. The impact of advanced age according to IPSSWM cut-off on the outcome of symptomatic and asymptomatic Waldenström's macroglobulinemia at diagnosis.
Ricci F; Tedeschi A; Vismara E; Greco A; Montillo M; Nichelatti M; Varettoni M; Lazzarino M; Morra E
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):124-6. PubMed ID: 21454211
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease status improved the response evaluation in patients with Waldenström's macroglobulinemia.
Xiong W; Wang Z; Wang T; Yu Y; Huang Y; Sun H; Chen J; Lyu R; Wang H; Yan Y; Wang Q; Liu W; An G; Sui W; Huang W; Zou D; Xiao Z; Wang J; Ouyang G; Qiu L; Yi S
Front Immunol; 2023; 14():1171539. PubMed ID: 37234167
[TBL] [Abstract][Full Text] [Related]
14.
Poulain S; Roumier C; Bertrand E; Renneville A; Caillault-Venet A; Doye E; Geffroy S; Sebda S; Nibourel O; Nudel M; Herbaux C; Renaud L; Tomowiak C; Guidez S; Tricot S; Roche-Lestienne C; Quesnel B; Preudhomme C; Leleu X
Clin Cancer Res; 2017 Oct; 23(20):6325-6335. PubMed ID: 28754818
[No Abstract] [Full Text] [Related]
15. Prognostic value of serum beta2-microglobulin in patients with Waldenstrom's macroglobulinemia requiring treatment.
Anagnostopoulos A; Zervas K; Kyrtsonis M; Symeonidis A; Gika D; Bourantas K; Zomas A; Anagnostopoulos N; Pangalis G; Dimopoulos MA;
Clin Lymphoma Myeloma; 2006 Nov; 7(3):205-9. PubMed ID: 17229336
[TBL] [Abstract][Full Text] [Related]
16. No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years.
Kastritis E; Kyrtsonis MC; Hatjiharissi E; Symeonidis A; Michalis E; Repoussis P; Tsatalas K; Michael M; Sioni A; Kartasis Z; Stefanoudaki E; Voulgarelis M; Delimpasi S; Gavriatopoulou M; Koulieris E; Gika D; Vervesou E; Konstantopoulos K; Kokkini G; Zomas A; Roussou P; Anagnostopoulos N; Economopoulos T; Terpos E; Zervas K; Dimopoulos MA
Am J Hematol; 2011 Jun; 86(6):479-83. PubMed ID: 21509798
[TBL] [Abstract][Full Text] [Related]
17. Waldenström's macroglobulinemia.
McKenna JA
Clin J Oncol Nurs; 2002; 6(5):283-6. PubMed ID: 12240489
[TBL] [Abstract][Full Text] [Related]
18. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
Vitolo U; Ferreri AJ; Montoto S
Crit Rev Oncol Hematol; 2008 Aug; 67(2):172-85. PubMed ID: 18499469
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).
Dhodapkar MV; Jacobson JL; Gertz MA; Rivkin SE; Roodman GD; Tuscano JM; Shurafa M; Kyle RA; Crowley JJ; Barlogie B
Blood; 2001 Jul; 98(1):41-8. PubMed ID: 11418461
[TBL] [Abstract][Full Text] [Related]
20. Waldenstrom's macroglobulinemia in the era of immunotherapy.
Vaxman I; Gertz M
Leuk Lymphoma; 2020 Jun; 61(6):1292-1304. PubMed ID: 31960730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
